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Irradiation in conjunction with gene therapy is considered for efficient cancer treatment. Mesenchymal stem cells (MSCs),
due to their irradiation-promotable tumor tropism, are ideal delivery vehicles for gene therapy. In this study, we investi-
gated whether treatment with radiation and interleukin (IL)-12-expressing MSCs (MSCs/IL-12) exerts improved antitumor
effects on murine metastatic hepatoma. HCa-I and Hepa 1-6 cells were utilized to generate heterotopic murine hepatoma
models. Tumor-bearing mice were treated with irradiation or MSCs/IL-12 alone, or a combination. Monocyte chemoattrac-
tant protein-1 (MCP-1/CCL2) expression was assessed in irradiated hepatoma tissues to confirm a chemotactic effect.
Combination treatment strategies were established and their therapeutic efficacies were evaluated by monitoring tumor
growth, metastasis and survival rate. IL-12 expression was assessed and the apoptotic activity and immunological altera-
tions in the tumor microenvironment were examined. MCP-1/CCL2 expression and localization of MSCs/IL-12 increased in
the irradiated murine hepatoma cells. The antitumor effects, including suppression of pulmonary metastasis and survival
rate improvements, were increased by the combination treatment with irradiation and MSCs/IL-12. IL-12 expression was
increased in tumor cells, causing proliferation of cluster of differentiation 81 T-lymphocytes and natural killer cells. The
apoptotic activity increased, indicating that the cytotoxicity of immune cells was involved in the antitumor effect of the
combined treatment. Treatment with irradiation and MSCs/IL-12 showed effectiveness in treating murine metastatic hepa-
toma. IL-12-induced proliferation of immune cells played an important role in apoptosis of tumor cells. Our results sug-
gest that treatment with irradiation and MSCs/IL-12 may be a useful strategy for enhancing antitumor activity in
metastatic hepatoma.
Hepatocellular carcinoma (HCC) is a major health problem
worldwide, with increasing incidence rates; HCC causes
almost one million deaths annually and generally develops
on a background of chronic inﬂammatory liver disease.1
Although HCC is the ﬁfth most common cancer in men and
seventh most common in women worldwide, its management
is difﬁcult because HCC typically arises and progresses early
on without associated symptoms or signs.2 Therefore, irradia-
tion to treat patients with late-stage hepatoma has been
increasingly selected as the therapeutic option in HCC
management.3
Radiation therapy uses high-energy radiation to destroy
cancer cells. It is employed as a component of adjuvant ther-
apy after surgery or in treatment of a primary malignant
tumor.4 However, irradiation is used carefully in HCC treat-
ment because liver tissues are highly susceptible to radiation
damage5 and some metastatic HCCs that originate elsewhere
can recur due to radioresistance.6 Combination treatments
utilizing gene therapy with irradiation have been applied to
overcome these shortcomings.7 Recently, irradiation has also
been used as a tool for enhancing the therapeutic effect by
modulation of the tumor microenvironment.8
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Bone marrow-derived mesenchymal stem cells (MSCs) are
adult pluripotent progenitor cells with the potential to differ-
entiate into osteoblasts, chondrocytes or adipocytes.9 MSCs
are emerging as cellular vehicles for anticancer gene delivery.
Representative antitumor molecules such as tumor necrosis
factor (TNF)-related apoptosis-inducing ligand or interleukin
(IL)-12 can easily transduce into the MSCs.10–12 Expression
of transgenes from engineered MSCs can be maintained for
up to 6 months because of their hypoimmunogenic proper-
ties. Moreover, MSCs themselves have an ability to migrate
which can be enhanced by irradiation into the neoplasm. The
therapeutic efﬁcacy of engineered MSCs is currently being
assessed in various cancer models.11,12
Gene-modiﬁed MSCs have been applied to HCC treatment
as a therapy directed toward the tumor stroma and angiogen-
esis.13 However, the investigation of gene-modiﬁed MSCs in
HCC treatment is a new area of research, compared to its
study and application in other cancers.11,12 There are also no
reports addressing the therapeutic effects of genetically modi-
ﬁed MSCs in extrahepatic metastasis, despite the occurrence
of metastasis in almost half of HCC patients.14 Therefore, fur-
ther studies are needed for establishing optimal strategies that
utilize gene-modiﬁed MSCs for treating metastatic HCC.
The IL-12 signaling pathways strongly highlight the
potential of this cytokine and its related molecules as rational
candidates for antitumor therapies. IL-12 expression at a
tumor site could attract activated lymphocytes. In addition,
IL-12 is critical for the development of the peritumoral
stroma required for accepting tumor-migrating T cells. Thus,
the level and duration of IL-12 at the tumor site may have a
major role in triggering tumor-speciﬁc immune responses.15
In this study, we generated gene-modiﬁed MSCs which
expressed HCC-targeted IL-12 selectively. By applying the IL-
12-expressing gene-modiﬁed MSCs (MSCs/IL-12) and
irradiation to murine metastatic hepatoma, we investigated
whether irradiation improved the therapeutic efﬁcacy of
MSCs/IL-12. Furthermore, we investigated whether this com-
bination therapy was efﬁcacious as an antitumor therapy by
monitoring the metastases, tumor formation and survival rate
in an extrahepatic metastatic model.
Material and Methods
Mice and tumor lines
Animal facilities were approved by the Association of
Assessment and Accreditation of Laboratory Animal Care
(AAALAC), and all experiments were executed under the insti-
tutional guidelines established by the Institutional Animal Care
and Use Committee at Yonsei University (IACUC-2012-0177).
All mice were raised with liberal access to food and water
under speciﬁc pathogen-free conditions in a room maintained
on a 12-hr light/dark cycle. All in vivo extractions were per-
formed under deep anesthetization or after euthanasia. Six- to
seven-week-old male C3H/HeN and C57BL6 mice were pur-
chased from Orientbio (Seong-Nam, South Korea). HCa-I16
and Hepa 1–6,17 murine hepatoma cell lines, were used for
tumor growth. And, mice were divided into six groups for the
experiment considering statistical signiﬁcance: Tumor control,
Single Irradiation (SIR), Fractionated Irradiation (FIR), MSCs/
IL-12, SIR1MSCs/IL-12, FIR1MSCs/IL-12.
Irradiation
The tumor bearing mouse was placed in an acrylic chamber
in order to immobilize the right leg without anesthesia. Lead
shields were used to avoid unwanted irradiation to other
body parts. Tumor irradiation was performed by an X-ray
irradiator (X-RAD 320, Precision X-Ray) using 2.0 mm Al
ﬁltration (300 kVp) at a dose of 10 Gy single or 2 Gy 3 5
(total 10 Gy) fractionation.
Preparation of gene-modified MSCs
MSCs/IL-12 were made with reference to the method that
has been established.12
Noninvasive in vivo bio-imaging system
MSCs/IL-12 were labeled with Dye eFluorV
R
670 Cell Labeling
(5 lM/1 3 106 cells, e-Bioscience, San Diego, CA), and in vivo
image was acquired using Xenogen In Vivo Imaging System
(IVISV
R
100 series, Caliper Life Science, Hopkinton, MA).
Pulmonary metastasis
Bouin’s solution was prepared using 75 ml saturated aqueous
solution of picric acid and 25 ml of 40% aqueous formalin
(Sigma, St. Louis, MO). Lungs were ﬁxed by submersion in
Bouin’s solution for 6 hr and ﬁxed lungs were transferred to
70% alcohol.
Sample preparation
Cultured medium of hepatoma cells were concentrated
using VIVASPINVR (Sartorius Stedim Biotech, Goettingen,
Germany). Tumor tissues were chopped to 4 mm2 and
What’s new?
Mesenchymal stem cells (MSCs) are promising gene-delivery vehicles, with the potential to improve antitumor effects when
used in combination with existing therapies. In the present study, the combined use of interleukin (IL)-12-expressing MSCs
(MSCs/IL-12) and radiation therapy increased antitumor activity in murine metastatic hepatoma, a model that is representative
of human metastatic hepatocellular carcinoma (HCC), which affects nearly half of HCC patients. Treatment with MSCs/IL-12
resulted in increased IL-12 expression in tumor cells and immune cell proliferation. Immune cell cytotoxicity, evidenced by
increased apoptotic activity, appeared to play a role in MSCs/IL-12 augmentation of antitumor effects.
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biopsies were homogenized in tissue protein lysis buffer
(Pierce, Rockford, IL). Homogenates were centrifuged
(13,000 RPM, 5 min), and protein supernatant was collected.
Splenocytes were isolated and cultured on CD3/CD28 coated
plate (BD bioscience, Franklin Lakes, NJ) for 2 days. Then,
the medium were concentrated. Allowed the blood to clot by
leaving it undisturbed at room temperature for 15 min.
Removed the clot by centrifuging at forces in excess of
7,500g for 10 min, and then the serum was collected. Each
protein extract was used for analyses in enzyme-linked
immunosorbent assay (ELISA) and Western blot. Total RNA
was extracted from hepatoma cells using a RNeasyV
R
mini kit
(QiagenVR , Hilden, Germany). cDNA was synthesized by
reverse transcription system (Promega, Fitchburg, WI) for
reverse transcription-PCR (RT-PCR). Tumor tissues were
embedded in parafﬁn block or frozen Tissue-TekVR OCTTM
compounds (Sakura Finetek, Alphen aan den Rijn, The Neth-
erlands), and 5 lm sections were attached to slides for
immunohistochemistry, immunoﬂuorescence and TUNEL
assay. Single cells for FACS analysis were isolated from
tumors as previously described.18
ELISA
Total protein concentration in each sample was deter-
mined using a BCA assay (Pierce, Rockford, IL), and
quantitative analysis of monocyte chemotactic protein-1
(MCP-1/CCL2), interleukin (IL) 12, interferon (IFN)-c and
alpha fetoprotein (AFP) expression was carried out using
MCP-1/CCL2, IL-12p70, IFN-c and AFP ELISA Set (BD
Pharmingen, Franklin Lakes, NJ) according to the manu-
facturer’s protocols.
Western blot
Protein lysates of tumor tissue were separated by electropho-
resis in 12–15% polyacrylamide gels and electrotransferred to
nitrocellulose membranes (GE Life sciences, Pittsburgh, PA).
Membranes were incubated overnight at 4C with the mono-
cyte chemoattractant protein-1 (MCP-1/CCL2), C-C chemo-
kine receptor type 2 (CCR2) and IL-12 antibody (1:500, 95
kDa, Bioss, Woburn, MA). Then, membranes were incubated
for 1 hr at room temperature in 1:1,000 diluted goat anti-
rabbit IgG, HRP conjugated (Bioss). Blots were developed
using chemiluminescent peroxidase substrate (Sigma-Aldrich,
St. Louis, MO) and exposed using X-ray ﬁlm and developer
(Agfa, Mortsel, Belgium). Densitometry measurements were
made using Image-J software (freeware; rsbweb. NIH. Gov/
ij).
RT-PCR
The 1 lg/ll cDNA was used for PCR. Primer pairs for
ampliﬁcation of endogenous MCP-1/CCL2 and GAPDH
were as follows: MCP-1/CCL2: 50 AGGTCCCTGTCATG
CTTCTG 30 and 50 TCTGGACCCATTCCTTCTTG 30;
GAPDH: 50 CGACTTCAACAGCAACTCCCACTCTTCC 30
and 50 TGGGTGGTCCAGGGTTTCTTACTCCTT 30.
Immunofluorescence
About 5 lm cryo-sectioned tumor tissues were incubated over-
night with the primary antibodies: polyclonal rabbit anti-MCP-
1/CCL2, Cluster Differentiation (CD) 90, CD73 and IL-12R
(1:500, Bioss). Sections were incubated with anti-rabbit second-
ary biotinylated antibody (1:1,000, Vector, Burlingame, CA)
and visualized with streptavidin conjugated to Fluorescein or
Texas red (Vector, Burlingame, CA).
Immunohistochemistry
About 5 lm sections of tumor tissues embedded in parafﬁn
were used for immunostaining with the ABC technique (Vec-
tor Elite Kit, Vector, Burlingame, CA). Sections were incu-
bated over two nights at 4C with monoclonal mouse anti-
CD38 and CD57 (1:500, Chemicon, CA) and rinsed with
0.05M phosphate buffer saline (PBS) and 3% normal goat
serum. Then, sections were incubated with the secondary bio-
tinylated antibody (1:200, Vector, Burlingame, CA) and
reacted with 0.5 mg/ml 3,30-diaminobenzidine tetrahydro-
chloride (DAB, Vector, Burlingame, CA). Reactions showed
under the light microscope, and the number of stained cells
was quantiﬁed by stereological analysis using Image-J soft-
ware (freeware; rsbweb. NIH. Gov/ij).
Cell migration assay
About 8 lm pore FluoBlokTM-inserts (Corning Life Science,
Tewksbury, MA) and 24-well plates were assembled as upper
and lower chambers. About 5 3 105 IL-12 expressing mesen-
chymal stem cells (MSCs/IL-12) were placed in the upper
chamber in the presence of 1 and 6 ng/ml recombinant
MCP-1/CCL2 (Prospec, Ness Ziona, Israel) for 48 hr. At the
end of incubation times, cells in the upper chamber were
removed with cotton swabs and cells that traversed the
membrane to the lower surface of the insert were ﬁxed with
4% paraformaldehyde. Fixed cells were stained with
Hoechst33342 (Thermo scientiﬁc, Pittsburgh, PA) and eval-
uated spectrophotometrically using a microplate reader (Syn-
ergy H4 hybrid reader, BioTek, Winooski, VT).
Immunocytochemistry
MSCs/IL-12 were cultured for 24 hr on bio-coated round
cover slip (BD bioscience, Bedford, MA). MSCs/IL-12
were ﬁxed on cover slip using 4% paraformaldehyde.
MSCs/IL-12-ﬁxed cover slips were incubated for 15 hr
with the primary antibodies: polyclonal rabbit anti-MCP-
1/CCL2 and -CCR2 (1:1000, Abcam, Cambridge, MA).
Then, cover slips were incubated with anti-rabbit second-
ary biotinylated antibody and visualized with streptavidin
conjugated to Fluorescein or Texas red (Vector, Burlin-
game, CA).
CD81 T-lymphocyte proliferation
Single cells were isolated from tumors as previously described
and washed in phosphate-buffered saline (PBS) before
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determining total cell numbers. Cells were resuspended to
approximately 1 3 106 cells/ml in ice cold PBS, 10% FCS
and 1% sodium azide, and 1 lg/ml of FITC-labeled anti-
mouse CD8 antibody (clone 53-6.72, e-Bioscience, San Diego,
CA) was added for 30 min at 4C. Cells were washed twice,
suspended in PBS and subjected to ﬂow cytometry on a BD
FACSVerseTM ﬂow cytometer (BD Bioscience, Franklin
Lakes, NJ). Data were analyzed using the FlowJo software
(Tree Star, Ashland, OR).
TUNEL assay
About 5 lm sections of tumor tissues embedded in parafﬁn
were stained with the DeadEndTM Colorimetric TUNEL
System (Promega, Madison, WI) according to the manufac-
turer’s protocol. Ten areas were randomly selected for each
tumor section.
Statistical analysis
All data are presented as mean6 standard error of the
mean (SEM). The one-way analysis of variance (ANOVA)
is used to determine whether there are any signiﬁcant dif-
ferences between the means of groups, depending on the
normality of the data. A difference of p< 0.05 was consid-
ered to be statistically signiﬁcant. All statistical analyses
were carried out using Sigma Stat (ver. 3.5, Systat Soft-
ware Inc., Chicago, IL).
Results
Irradiation-induced expression of monocyte
chemoattractant protein-1 in hepatoma cell lines
and tissues
Expression of MCP-1/CCL2 was conﬁrmed in HCa-I and
Hepa 1-6 hepatoma cells irradiated with 10 Gy of irradiation.
In the cultured medium, MCP-1/CCL2 levels began to
increase 7 hr after and to decrease on Day 5 after irradiation.
MCP-1/CCL2 expression was maximal on Day 1 (Fig. 1a).
Endogenous expression of the MCP-1/CCL2 gene was also
increased in the irradiated hepatoma cells. Analyses of MCP-
1/CCL2 expression over time indicated that MCP-1/CCL2
levels began to increase 1 hr after and to decrease on day 5
following irradiation. The maximum expression of endoge-
nous MCP-1/CCL2 was observed on Day 1, similar to its
expression proﬁle in the cultured medium (Fig. 1b). Using
hematoxylin and eosin (H&E) staining, we evaluated tumor
density to determine an optimal site for immunoﬂuorescence
analysis (Fig. 1c). A 10-Gy irradiation was separated into a
single irradiation dose (SIR) or a ﬁve-way fractional dose
(FIR) in the in vivo study. The expression of MCP-1/CCL2
was investigated in tumor tissues on Day 5 after the ﬁrst irra-
diation. In hepatoma tissues, irradiation increased the expres-
sion of MCP-1/CCL2 (Fig. 1c). Western blot analysis showed
the increased expression of MCP-1/CCL2 in the SIR and FIR
groups (irradiated groups), compared to that in the tumor
controls (Fig. 1d).
Gene-modified MSCs/IL-12 were able to localize to the
region corresponding to the MCP-1/CCL2 expression
A method of coxsackievirus-adenovirus receptor (CAR)-inde-
pendent internalization was used for transduction of
recombinant adenovirus (rAd) into MSCs (Fig. 2a). The che-
motactic effect of MCP-1/CCL2 was investigated in cultured
MSCs/IL-12. The migratory ability of MSCs/IL-12 was
enhanced by treatment with recombinant MCP-1/CCL2, but
there was no signiﬁcant difference in the migration of cell
treated with doses between 1 and 6 ng/ml of MCP-1/CCL2
(Fig. 2c). C-C chemokine receptor type 2 (CCR2), the MCP-
1/CCL2 receptor, was expressed in easily detectable amounts
on MSCs/IL-12 treated with 1 ng/ml MCP-1CCL2 (Fig. 2b;
non-merged images are shown in Supporting Information
Fig. 1A). MSCs/IL-12 were intratumorally injected to investi-
gate whether MSC/IL-12 localization reﬂected the changes in
MCP-1/CCL2 expression in irradiated hepatoma tissues.
Hepatoma tissues were immunostained for both cluster of
differentiation (CD)73 and CD90, two well-known markers
for identifying MSCs,19 to conﬁrm the presence of MSCs/IL-
12 in the irradiated hepatoma tissues. Although the MSCs/
IL-12 were detectable within the tumor 30 min after injection
of MSCs/IL-12, the localization of MSCs/IL-12 was well-
maintained in the tumor microenvironment of the irradiated
hepatoma up to Day 5 of injection, compared to the non-
irradiated hepatomas (Figs. 2d and 2e). Quantitative analysis
indicated the signiﬁcant enhancement of MSCs/IL-12 local-
ization into the hepatoma treated with the combination of
irradiation and MSCs/IL-12 (Fig. 2f).
Establishment of therapeutic strategies for combination
treatment with irradiation and MSCs/IL-12
Novel therapeutic strategies were devised targeting murine
metastatic hepatoma based on the data described in the
Figures 1 and 2. HCa-I and Hepa 1–6 (1 3 106) cells were
injected into the right thighs of mice, and tumors were
grown until they were 8 mm in size. The mice were irradi-
ated with a single dose of 10 Gy or with ﬁve doses of 2 Gy
(total of 10 Gy). MSCs/IL-12 were sub-cultured for 24 hr
and injected intratumorally, for the ﬁrst time 7 hr after
irradiation. As a MCP-1/CCL2 expression was reduced
starting on Day 5 post-irradiation (Figs. 1a and 1b), MSCs/
IL-12 cells were injected once again on post-irradiation
Day 7 to boost the efﬁcacy of the treatment. The tumor
volume and survival rate were measured from the ﬁrst day
of the experiment, and the lungs were harvested on experi-
mental Day 14 or 20 for analysis of metastasis (Fig. 3a).
Combination treatment with irradiation and MSCs/IL-12
had increased antitumor and anti-metastatic effects
The tumor growth and metastasis were signiﬁcantly inhibited
by the combined treatment, compared to treatment with irra-
diation or MSCs/IL-12 alone. Tumor volume was signiﬁ-
cantly decreased in the FIR1MSCs/IL-12 group between
post-irradiation Days 15 and 17 in HCa-I tumors and
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between post-irradiation Days 11 and 17 in Hepa 1–6
tumors, compared to the other treatment groups (Figs. 3b
and 3d). Representative images of tumor growth in mice that
received the different treatments are shown in Supporting
Information Figure 1B. The metastatic nodules signiﬁcantly
decreased in the FIR1MSCs/IL-12 group, although there
was some suppression of metastasis in the MSCs/IL-12 and
SIR1MSCs/IL-12 groups as well (Figs. 3f and 3g). The sur-
vival rate was 30–40% in the single treatment groups and
70–90% in the combination treatment group, based on the
decreased tumor volume and pulmonary metastasis analyses,
respectively (Figs. 3c and 3e). The antitumor effects of MSCs/
IL-12 were better in the combination treatment group that
received the fractionated irradiation dose, compared to those
in a group that received the single dose.
Irradiation-mediated increase in localization
of MSCs/IL-12 enhanced IL-12 expression in murine
metastatic hepatoma
The IL-12 expression level was assessed in the cultured media
of MSCs/IL-12. The expression of IL-12 in MSCs/IL-12
increased gradually in proportion to the rAd concentration,
and IL-12 started to increase signiﬁcantly when the multiplic-
ity of infection (MOI) 50 (Fig. 4a). As the titer of rAd
increased, the expression levels of IL-12 also increased. How-
ever, the viability of MSCs was negatively affected by infec-
tion with viral doses 100 MOI (data not shown). Therefore,
an MOI of 50 of IL-12-expressing rAd was determined to be
the optimal condition for transduction. As MSCs/IL-12
became more localized within the irradiated tumor tissues
due to the chemotactic effect of MCP-1/CCL2, the expression
Figure 1. Irradiation enhanced MCP-1/CCL2 expression. (a, b) Chronological changes of MCP-1/CCL2 expression in cultured medium (a)
and mRNAs (b) of irradiated hepatoma cell lines. (c) Increased expression of MCP-1/CCL2 in irradiated hepatoma tissues. (d) Western blot
for MCP-1/CCL2 expression (11 kDa) in protein lysates of hepatoma and quantification analyses. *p<0.05; **p<0.001 (vs. tumor control).
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Figure 2. Irradiation induced localization of MSCs/IL-12 in murine hepatoma. (a) Illustration of MSCs/IL-12 manufacture. (b) CCR2 expres-
sion in MSCs/IL-12 by the treatment of 1 ng MCP-1/CCL2. (c) The migration ability of MSCs/IL-12 with recognition to different dose of MCP-
1/CCL2. (d) Noninvasive imaging of MSCs/IL-12. (e) Co-localization of CD73 and CD90 as merged images at 203 magnification. Scale bars,
50 lm. (f) Quantitative analyses of co-locally expressed CD73 and CD90 cells per total cells in five randomly selected tumor sections.
*p<0.05 (vs. tumor control); **p<0.001. Results are mean6S.E.M.
Figure 3. Investigation of antitumor effects to the murine hepatoma with establishment of treatment strategies using the combined treat-
ments. (a) Treatment strategies for combination treatment with irradiation and MSCs/IL-12. (b and d) Comparison of tumor growth.
*p<0.05; **p<0.001; #p<0.05 (vs. Group 5). (c and e) Survival rate was analyzed by a log-rank test based on the Kaplan–Meier method.
*p<0.05 (vs. Group 1–4), **p<0.001 (vs. Group 1–5). (f) Representative images about pulmonary metastasis (black arrows). (g) Quantita-
tive analysis of the metastatic nodule number of pulmonary. *p<0.05 (vs. Group 1–3); #p<0.001 (vs. Group 1–4); $p<0.001 (Group 1–
5). Results are mean6S.E.M.
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of IL-12 in the tumor microenvironment was investigated on
the last day on which the tumor growth was measured. IL-12
expression in tumor lysates was signiﬁcantly increased in the
combination treatment group (Fig. 4b). Moreover, the expres-
sion of the IL-12 receptor (IL-12R) was signiﬁcantly
increased in many cells within the tumor microenvironment
in the combination treatment group (Figs. 4c and 4d).
Induction of interferon-c expression by IL-12-induced CD81
T-lymphocytes and natural killer cells
Proliferation of CD81 T-lymphocytes and natural killer (NK)
cells in the tumor microenvironment was investigated to delin-
eate the mechanism underlying the antitumor effects of
enhanced IL-12 expression (Figs. 5a and 5b). Proliferation of
CD81 T-lymphocytes was signiﬁcantly increased to
29.16 3.4% in the SIR1MSCs/IL-12 group and to 386 2.8%
in the FIR1MSCs/IL-12 group (Fig. 5a). The combination
treatment groups also showed increases in the number of acti-
vated NK cells, which was conﬁrmed by staining for the CD57
marker in the hepatoma tissues (Fig. 5b). The results of the
quantitative analysis of marker expression are shown in Sup-
porting Information Figure 1C. Next, the IFN-c expression
level in the tumor tissue, splenocytes and blood serum was
assessed. In tumor tissues and splenocytes, IFN-c expression
was signiﬁcantly increased in the combination treatment
group. IFN-c expression in the MSCs/IL-12 group was
increased only in the protein lysates of hepatoma tissues. The
results of IFN-c expression analysis in sera showed IFN-c in
the FIR1MSCs/IL-12 group alone (Fig. 5c).
Apoptotic activity increased in the murine metastatic
hepatoma
The tumor cells in mice that received the combination treat-
ment exhibited increased apoptosis (to 43.66 5.3%) in the
SIR1MSCs/IL-12 and FIR1MSCs/IL-12 groups (to
52.36 3.6%), compared to those that received the single treat-
ment (Fig. 6). Although this increased apoptosis was lower
than that observed in the combination treatment group, the
proportion of apoptotic cells was also increased in the single
treatment groups, compared to corresponding untreated tumor
controls (Fig. 6; to 35.26 4.1% in the SIR, to 32.16 2.8% in
the FIR, and to 25.66 2.4% in the MSCs/IL-12 groups).
Discussion
Curative treatments for HCC include radical resection of
tumor and liver transplantation has strict criteria for candi-
date selection or ﬁnding organ donors. Although percutane-
ous ethanol injection and radio frequency ablation have
helped improve the prognosis of HCC patients in recent
years, the narrow range of patient selection, non-speciﬁc
tumor killing and the impact on remaining liver function are
some of the disadvantages of these additional therapies. To
address these and other disadvantages in current treatment
options for HCC, new strategies that can be applied more
readily to a wider patient population and that speciﬁcally
Figure 4. Measurement of IL-12 expression induced by MSCs/IL-12. (a) Comparison of IL-12 expression by different concentration of rAd/
IL-12. The gray-line box indicates the optimal concentration of rAd/IL-12 for transduction into the MSCs. (b) Western blot for IL-12 expres-
sion (25 kDa) in protein lysates of hepatoma and quantification analyses. (c) Immunofluorescence shows an expression of IL-12R. Scale
bars, 50 lm. (d) Quantitative analyses of the IL-12R expression cells per total cells in five randomly selected tumor sections. The statistical
significance of all data was shown by *p<0.05 and **p<0.001. Results are mean6S.E.M.
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target tumors with minimal inﬂuence on any normal liver
tissues are needed urgently. A number of strategies are being
evaluated currently, including gene- and immunotherapies
based on suicide, cytokine and anti-angiogenic factors. Gene-
modiﬁed MSCs have been investigated as a novel anticancer
therapeutic option in a murine HCC model in recent years.13
Nevertheless, there are few reports of their application and
curative efﬁcacy in HCC treatment.
We used the xenogeneic MSCs from rat bone marrow.
When injected into mice, a total MSCs population will
decrease to less than 20% by generations of MSC-speciﬁc
antibodies (data not shown).20 However, the use of syngeneic
MSCs has safety concerns. Syngeneic MSCs can transform in
vivo with repeated replication.21 Generation of MSCs by
repeated replication in the tumors might have the secondary
effect of promoting tumorigenesis or metastasis.22 Therefore,
Figure 5. Proliferation of CD81 T-lymphocytes and NK cells induced IFN-c expression. (a) FACS analysis of CD81 T-lymphocytes proliferation
among quantified total cells of the hepatoma. The horizontal axis represents the density range of FITC-A, and the vertical axis represents the count
of CD81 T-lymphocytes. Percent values in the histogram represent the mean of CD81 T-lymphocytes per total cells. (b) Confirmation of activated
NK cells in the hepatoma tissues. Scale bars, 50 lm. (c) Comparison of IFN-c expression in the protein extracts from tumor, splenocytes and blood.
*p<0.05 and **p<0.001. Results are mean6S.E.M.
Figure 6. Apoptotic activities to the murine metastatic hepatoma. (a) Microscopic images show apoptotic activities in the tumor tissues.
Scale bars, 1 mm. (b) Quantitative analysis of apoptotic activities was indicated as the percent of apoptotic bodies per 2,000 nuclei. The
statistical significance of all data was shown by *p<0.05 and **p<0.01. Results are mean6S.E.M.
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we utilized xenogeneic MSCs to inhibit the excessive replica-
tion of MSCs. And, our treatment strategies suggested once
more injection of the MSCs/IL-12 at 7days after the ﬁrst
injection than several times injection. No studies have
reported abnormal transformation of xenogeneic MSCs
in vivo.
rAd is one of the most potent vectors used in gene deliv-
ery in vitro and in vivo due to its broad tropism, ease of
manufacture and low risk of insertional mutagenesis. How-
ever, it has some concerns by an immune response to viral
proteins.23 In our previous study, we conﬁrmed the activity
of immune cells using MSC transduced with Ad constructs
lacking IL-12. Our previous reports had used MSCs which
transfected with mock recombinant adenovirus as a control.
Judging from our previous results, there were no effects on
the immune cell activity in the treatment of the na€ıve MSCs
or the mock rAd-transduced MSCs.11,12,24 The neutralizing
Ab assay also indicated that it could not hinder therapeutic
effects mediated by MSCs/rAd (IL-12 lacking) and na€ıve
MSCs (data not shown). Therefore, immune response against
the rAd or the na€ıve MSCs was negligible in our system.
MSCs migrated via the chemotactic effects of the MCP-1/
CCL2 that is secreted from tumor or immune cells.25 Our
data show that the expression of MCP-1/CCL2 was signiﬁ-
cantly increased in the irradiated hepatoma cell, compared to
non-irradiated cells. This increased expression of MCP-1/
CCL2 in the combination treatment with MSCs/IL-12 and
irradiation could enhance the localization of MSCs/IL-12,
improving the treatment efﬁcacy in the murine HCC model.
We also conﬁrmed that the expression of CCR2, a receptor
for the MCP-1/CCL2 ligand, was also increased in the tumor
tissues in the combination treatment group (Supporting
Information Fig. S2). These data indicate that MSCs/IL-12
cells were “honed” to tumor cells, via a mechanism involving
their interaction with the enhanced levels of MCP-1/CCL2 in
the irradiated hepatoma tissue. We also conﬁrmed the
expression of stromal-derived factor (SDF)-1a, a known che-
moattractant that promotes MSC growth.26 However, the
expression level of SDF-1a in irradiated hepatoma was not
signiﬁcantly different, compared to the non-irradiated con-
trols (data not shown).
In this study, we sought to examine whether the therapeu-
tic potential of genetically modiﬁed MSCs could be enhanced
in a murine hepatoma model, based on injection of HCa-1
and Hepa 1-6 cells into mice. HCa-I cells are highly radiore-
sistant and undergo spontaneous pulmonary metastasis.18 We
also evaluated the therapeutic efﬁcacy of the combined treat-
ment, using the Hepa 1-6 tumor model to rule out tumor
speciﬁcity. Hepa 1-6 cells form tumors in C57/BL6 mice
spontaneously.27 It is possible to utilize these cell lines as
orthotopic models, because they have the tumorigenic ability
in liver (Supporting Information Fig. S3A). However, utilizing
an orthotopic model in mice is difﬁcult, since precision dur-
ing irradiation at the tumor site in mice is not as facile as it
is in humans. To circumvent this limitation, we conﬁrmed
the expression of alpha fetoprotein (AFP) in the tumor tissue
and serum samples in the irradiated mice (Supporting Infor-
mation Fig. S3B). AFP, which is measured in serum as a con-
stituent of the screening test for a subset of developmental
abnormalities, is elevated in a person with HCC. A recent
study also indicated that the expression of tumor-associated
glycoprotein (TAG)-72 is increased in HCC involving
metastasis to the lymph node.28 Therefore, we conﬁrmed
expression of TAG-72 to support the rationale of using
the invasive HCa-I cell line (Supporting Information Fig.
S3C).
Tumor recurrence after radiotherapy increases in HCC
patients who have decreased IL-12 levels in serum (treatment
failure in 18 patients in a total of 25 patients; p< 0.043,
unpublished data). We chose to modify MSCs by increasing
the expression of IL-12 in MSCs to overcome the immuno-
logical shortcoming brought about by reducing IL-12 expres-
sion in HCC. In addition, induction of IL-12 over-expression
would facilitate the recognition of cancer cells by cytotoxic
T-lymphocytes.29 Our data showed increased proliferation of
CD81 T-lymphocytes and NK cells in the tumor microenvir-
onment, indicating a direct cytotoxic activity and induction
of apoptosis, following enhancement of IFN-c expression.
Therefore, our results provide a basis for a clinical strategy to
induce a strong tumor-speciﬁc immune response using IL-12
gene-based immunotherapy in combination with irradiation.
Moreover, the combined treatment is expected to compensate
for the disadvantages of irradiation alone, by attenuating the
tumor recurrence and metastasis promoted by radioresistant
of cancer.30
We also investigated the inﬂux of endogenous MSCs in
the tumor microenvironment of irradiated mice to conﬁrm
recruitment of MSCs by irradiation (Supporting Information
Fig. S4). Endogenous MSCs could also be recruited by the
chemoattractant effect of MCP-1/CCL2. However, endoge-
nous MSCs did not alter the antitumor effects of irradiation
and/or the combined treatments. Although endogenous
MSCs did not affect antitumor activity, recruitment of endog-
enous MSCs by irradiation may be considered for further
development as a target for potential tumor treatment.31,32
We established two different irradiation plans using SIR
and FIR. Many antitumor studies utilizing irradiation focus
primarily on the effects of single-dose irradiation. However,
we also utilized a fraction-dose irradiation protocol. Our data
showed that the combination with fractionated irradiation
and MSCs/IL-12 showed better efﬁcacy, as indicated by its
effect on tumor growth and metastasis. A hypofractionated
radiation, such as is used for stereotactic body radiotherapy,
and combination treatment with gene therapy have focused
on hyperfractionated irradiation in low doses.33,34 However,
selecting optimal irradiation doses for gene therapeutics has
been controversial. Our future studies will address the differ-
ences between the two treatments and we expect these studies
to provide important information on the immune responses
of the tumor microenvironment.
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In conclusion, increased expression of MCP-1/CCL2 in
irradiated hepatoma induced localization of MSCs/IL-12,
and consequently, the IL-12 expression is increased in the
tumor microenvironment. The inhibition of tumor growth
and pulmonary metastasis results in increased cytotoxic activ-
ity in metastatic hepatoma, promoted by the IL-12-induced
proliferation of CD81 T-lymphocytes and NK cells, ultimately
resulting in signiﬁcant improvements in the survival rate.
Taken together, our results suggest that combination treat-
ment with irradiation and MSCs/IL-12 is a potential strategy
for effective treatment of metastatic hepatoma through
immune modulation of the tumor microenvironment.
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